TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30776019

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30776363

Group type: EXPERIMENTAL
Intervention: Injection of 1.5 mg of paclitaxel
Number of subjects: 23
Study: 30776452

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d for 12 months
Number of subjects: 60
Study: 30776920

Group type: EXPERIMENTAL
Intervention: sST2 in HFpEF
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: sST2 in HFrEF
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: sST2 in HFpEF and HFrEF
Number of subjects: 193
Study: 30776994

Group type: EXPERIMENTAL
Intervention: Balloon Guide Catheter (BGC)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Conventional Guide Catheter
Number of subjects: 445

Group type: COMPARATOR
Intervention: Distal Access Catheter
Number of subjects: 445
Study: 30777020

Group type: EXPERIMENTAL
Intervention: Breastfeeding Self-Efficacy Scale to Measure Exclusive Breastfeeding (BSES-EBF)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: BSES-EBF Scale
Number of subjects: 477
Study: 30777022

Group type: EXPERIMENTAL
Intervention: 22 weekly group sessions called School of Health for Older People
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving the intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-utility analysis from a health system perspective
Number of subjects: 0
Study: 30777049

Group type: EXPERIMENTAL
Intervention: Patient education and exercise therapy (group-based program with 2 sessions of education and 8 weeks of supervised exercises)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education of clinicians (two-days course for physiotherapists and chiropractors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National level effects
Number of subjects: 0
Study: 30777085

Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 447
Study: 30777448

Group type: EXPERIMENTAL
Intervention: Prenatal smoke exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-exposed to prenatal smoke)
Number of subjects: 0
Study: 30777842

Group type: EXPERIMENTAL
Intervention: Early discharge based on a pre-specified set of risk criteria
Number of subjects: 502

Group type: COMPARATOR
Intervention: Standard discharge management
Number of subjects: 502
Study: 30777840

Group type: EXPERIMENTAL
Intervention: Pre-frail group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 90
Study: 30777875

Group type: EXPERIMENTAL
Intervention: Alisertib (80 mg/m2)
Number of subjects: 139
Study: 30778280

Group type: EXPERIMENTAL
Intervention: rTMS combined with Intensive Language-Action Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30778345

Group type: EXPERIMENTAL
Intervention: Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30778520

Group type: EXPERIMENTAL
Intervention: Letrozole followed by trastuzumab-pertuzumab for five cycles in molecular responders
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel for 13 weeks combined with trastuzumab-pertuzumab in molecular non-responders
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype in molecular responders
Number of subjects: 64
Study: 30779631

Group type: EXPERIMENTAL
Intervention: Dietary protein intake
Number of subjects: 0
Study: 30779990

Group type: EXPERIMENTAL
Intervention: selonsertib
Number of subjects: 1667
Study: 30780166

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.01, 0.05, 0.10 and 0.15 µg/kg/min; 15 minutes at each step)
Number of subjects: 10
Study: 30781469

Group type: EXPERIMENTAL
Intervention: Socioecological theory-based exercise facilitation contacts over 50 weeks
Number of subjects: 449

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 449
Study: 30782111

Group type: EXPERIMENTAL
Intervention: Measures of attitudes (21 items, alpha = 0.84)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Measures of perceived behavioral control (10 items, alpha = 0.85)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Measures of subjective norms (9 items, alpha = 0.89)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Overall model fit
Number of subjects: 1964
Study: 30782342

Group type: EXPERIMENTAL
Intervention: Awake-regional anaesthesia
Number of subjects: 722

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 722
Study: 30782413

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 0
Study: 30782509

Group type: EXPERIMENTAL
Intervention: Visceral obesity assessed by VFA
Number of subjects: 229

Group type: COMPARATOR
Intervention: Central obesity measured by WC
Number of subjects: 229
Study: 30782589

Group type: EXPERIMENTAL
Intervention: EPAD Longitudinal Cohort Study (LCS)
Number of subjects: 0
Study: 30782611

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and fludarabine lymphodepletion followed by CD19 CAR T cells
Number of subjects: 0
Study: 30782670

Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 505
Study: 30782684

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 370
Study: 30782698

Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Liposomal lidocaine 4% cream (topical anaesthetic)
Number of subjects: 346
Study: 30782707

Group type: EXPERIMENTAL
Intervention: Fortnightly finger prick capillary blood sampling
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Collection of stool samples and vaginal swabs each trimester, at delivery and postpartum
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nested case-control analysis comparing perturbations of transcript abundance in capillary blood
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: RNA profiles of circulating, non-coding RNA in cord blood serum
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Placenta tissue of preterm and term neonates
Number of subjects: 400
Study: 30782737

Group type: EXPERIMENTAL
Intervention: National Early Warning Score (NEWS) alone
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: NEWS combined with inflammatory markers (WCC, PCT, MR-proADM)
Number of subjects: 1303

Group type: COMPARATOR
Intervention: NEWS alone
Number of subjects: 1303
Study: 30782744

Group type: EXPERIMENTAL
Intervention: Age-related comorbidities (ARCs)
Number of subjects: 1415
Study: 30782749

Group type: EXPERIMENTAL
Intervention: ACT-based workshop intervention for increasing bouted MVPA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Weekly emails and monthly phone calls for 3 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Assessments at baseline, 3 months, and 6 months
Number of subjects: 48
Study: 30782760

Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children (intervention)
Number of subjects: 120
Study: 30782892

Group type: EXPERIMENTAL
Intervention: Community level intervention for pre-eclampsia led by community health workers
Number of subjects: 9172

Group type: EXPERIMENTAL
Intervention: Ordinary least squares model
Number of subjects: 9172
Study: 30782924

Group type: EXPERIMENTAL
Intervention: Minor trauma care delivered in a general practice
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hospital treatment for non-complex fractures or dislocations
Number of subjects: 200
Study: 30782925

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) assessed using validated instruments at baseline, 1, 6, and 12 months follow-up.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Standardised transthoracic echocardiograms and 6-minute walk tests at baseline and at 1 and 12 months after discharge.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Collection of blood and urine samples at baseline, 1 and 12 months follow-up.
Number of subjects: 5000
Study: 30782948

Group type: EXPERIMENTAL
Intervention: Xpert CT/NG
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: OSOM TV
Number of subjects: 247

Group type: COMPARATOR
Intervention: Anyplex II STI-7 Detection
Number of subjects: 247
Study: 30782999

Group type: EXPERIMENTAL
Intervention: Levofloxacin (750- to 1,000-mg once-daily dosing)
Number of subjects: 23
Study: 30783204

Group type: EXPERIMENTAL
Intervention: Eribulin mesilate (1.6 mg/m²) in combination with capecitabine (1000 mg/m² twice daily)
Number of subjects: 34
Study: 30783888

Group type: EXPERIMENTAL
Intervention: ALLN-177 (7,500 units/meal, 3 times a day)
Number of subjects: 16
Study: 30784639

Group type: EXPERIMENTAL
Intervention: Radial-only access (RA)
Number of subjects: 3790

Group type: COMPARATOR
Intervention: Radial-femoral access (RFA)
Number of subjects: 3790

Group type: COMPARATOR
Intervention: Femoral-only access
Number of subjects: 3790
Study: 30784647

Group type: EXPERIMENTAL
Intervention: Paladin System (angioplasty balloon with integrated embolic protection filter)
Number of subjects: 106
Study: 30784680

Group type: EXPERIMENTAL
Intervention: Modified HEART Score and High-Sensitivity Cardiac Troponin
Number of subjects: 0
Study: 30784685

Group type: EXPERIMENTAL
Intervention: Micra implantation
Number of subjects: 201
Study: 30784691

Group type: EXPERIMENTAL
Intervention: PPG algorithm using a commercially available smartwatch
Number of subjects: 508

Group type: COMPARATOR
Intervention: Cardiologists' diagnosis by electrocardiography (ECG)
Number of subjects: 508
Study: 30785625

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2215
Study: 30785829

Group type: EXPERIMENTAL
Intervention: Nivolumab plus low-dose ipilimumab (nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Nivolumab plus low-dose ipilimumab
Number of subjects: 288
Study: 30786000

Group type: EXPERIMENTAL
Intervention: Peripheral arterial stiffness (AS) defined as an ankle-brachial index (ABI) >1.2
Number of subjects: 264

Group type: COMPARATOR
Intervention: Normal ABI
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Peripheral arterial stiffness (AS) with concomitant asymptomatic peripheral arterial disease (aPAD)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Peripheral arterial stiffness (AS)
Number of subjects: 264
Study: 30786188

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (10 mg/kg) administered intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.
Number of subjects: 108
Study: 30786996

Group type: EXPERIMENTAL
Intervention: Elective shoulder replacement surgery
Number of subjects: 51895
Study: 30787085

Group type: EXPERIMENTAL
Intervention: Patient Information Leaflets (PILs) given by physicians along with an oral explanation.
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Patient Information Leaflets (PILs) given by physicians.
Number of subjects: 324
Study: 30787124

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30787176

Group type: EXPERIMENTAL
Intervention: TAS0728, a covalent-binding HER2-selective kinase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAS0728
Number of subjects: 0
Study: 30787625

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg SC every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab 40 mg SC every 2 weeks/weekly
Number of subjects: 0
Study: 30787641

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (300 mg daily)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of Vitamin D3 and Omega-3 fatty acids
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (Vitamin D3 alone)
Number of subjects: 86
Study: 30787930

Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-regulatory cells
Number of subjects: 0
Study: 30788134

Group type: EXPERIMENTAL
Intervention: Pharmacist-administered HIV point-of-care testing (POCT) with pre/post-test counseling and linkage to care plans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-administered HIV point-of-care testing (POCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacy-based HIV testing model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based research approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multipronged promotion campaign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preliminary costing assessment
Number of subjects: 0
Study: 30788136

Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Music listening (control)
Number of subjects: 0
Study: 30788571

Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy (SCP)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Native Tissue Repair (NTR)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Vaginal Mesh Repair (VMR)
Number of subjects: 213
Study: 30788718

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 30789648

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Stereotactic Ablative Radiotherapy (SABR) followed by surgery 10 weeks later
Number of subjects: 40
Study: 30789827

Group type: EXPERIMENTAL
Intervention: 12-week intensive outpatient rehabilitation including memantine and morphine treatment, psychological and physiotherapeutic intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 12-week intensive outpatient rehabilitation
Number of subjects: 10
Study: 30790030

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 95
Study: 30790296

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30790403

Group type: EXPERIMENTAL
Intervention: AV-1451
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cognitively normal controls
Number of subjects: 27
Study: 30790469

Group type: EXPERIMENTAL
Intervention: Palliative gastric radiotherapy (36 Gy in 12 daily fractions)
Number of subjects: 50
Study: 30790695

Group type: EXPERIMENTAL
Intervention: Contact-free monitoring of respiratory rates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30791143

Group type: EXPERIMENTAL
Intervention: MMR/Hib-MenC vaccination
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (MMR/Hib-MenC-naïve)
Number of subjects: 311
Study: 30791951

Group type: EXPERIMENTAL
Intervention: Frequent breakfast consumption (6 to 7 days/week)
Number of subjects: 6228

Group type: COMPARATOR
Intervention: Rare breakfast consumption (0 to 2 days/week)
Number of subjects: 6228

Group type: COMPARATOR
Intervention: Occasional breakfast consumption (3 to 5 days/week)
Number of subjects: 6228

Group type: COMPARATOR
Intervention: Daily breakfast consumption
Number of subjects: 6228
Study: 30792190

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clarithromycin, pomalidomide, and dexamethasone (ClaPd)
Number of subjects: 120
Study: 30792199

Group type: EXPERIMENTAL
Intervention: ADAMTS13 activity
Number of subjects: 0
Study: 30792246

Group type: EXPERIMENTAL
Intervention: Active smokers at time of surgery
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients with high clonality (above 26.8%)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Persistence of similar TCR repertoire at postoperative endoscopy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients with high clonality
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clonal T cell expansions
Number of subjects: 57
Study: 30792251

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 224
Study: 30792873

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 25
Study: 30792945

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS; based on 28 genomic variants)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Conventional risk score (CRS; based on traditional risk factors)
Number of subjects: 203
Study: 30793003

Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Patients with postherpetic neuralgia (PHN)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Patients who developed PHN
Number of subjects: 391
Study: 30793242

Group type: EXPERIMENTAL
Intervention: Postoperative reintervention
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Surgical site infection
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Distant metastasis
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Prolonged LOS (> 14 days)
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Cluster analysis results
Number of subjects: 1955
Study: 30793351

Group type: EXPERIMENTAL
Intervention: Person-centred inpatient care intervention including systematically applied person-centred assessment, health plans, and persistent PCC.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (pre-intervention data)
Number of subjects: 204
Study: 30793701

Group type: EXPERIMENTAL
Intervention: Drugs associated with drug-induced lupus (DIL)
Number of subjects: 12166
Study: 30794033

Group type: EXPERIMENTAL
Intervention: Induced subgroups from empirical data on treatment effectiveness
Number of subjects: 0
Study: 30795749

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Changes in self-focused attention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Changes in social self-efficacy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estimated social costs
Number of subjects: 60
Study: 30795797

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cells (MSCs) embedded in tricalcium phosphate
Number of subjects: 11
Study: 30795810

Group type: EXPERIMENTAL
Intervention: ActiGraph GT3X+
Number of subjects: 50
Study: 30795996

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg; administered intravenously weekly for 2 cycles, every 2 weeks for 4 cycles, and every 4 weeks thereafter)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 36
Study: 30796032

Group type: EXPERIMENTAL
Intervention: MTI-31 (LXI-15029), a novel mTORC1/mTORC2 inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTI-31 (LXI-15029)
Number of subjects: 0
Study: 30796035

Group type: EXPERIMENTAL
Intervention: ADI-PEG20 (36 mg/m weekly) with pemetrexed and cisplatin (ADIPEMCIS)
Number of subjects: 10
Study: 30796037

Group type: EXPERIMENTAL
Intervention: Biomarker assays for assessing EGFR abnormalities
Number of subjects: 0
Study: 30796113

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern
Number of subjects: 18429

Group type: EXPERIMENTAL
Intervention: Western dietary pattern
Number of subjects: 18429

Group type: EXPERIMENTAL
Intervention: Provegetarian dietary pattern
Number of subjects: 18429
Study: 30796119

Group type: EXPERIMENTAL
Intervention: Real-world data collection on MBC management
Number of subjects: 16700

Group type: EXPERIMENTAL
Intervention: Ancillary research projects
Number of subjects: 16700
Study: 30796155

Group type: EXPERIMENTAL
Intervention: Genexol-PM (230 mg/m2) plus cisplatin
Number of subjects: 52
Study: 30796299

Group type: EXPERIMENTAL
Intervention: Urine metabolomics analysis during normal pregnancy progression
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urine metabolomics for early prediction of gestational diabetes mellitus (GDM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urine metabolomics for early prediction of spontaneous abortion (SA)
Number of subjects: 50
Study: 30796821

Group type: EXPERIMENTAL
Intervention: Docetaxel with trastuzumab and pertuzumab
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Paclitaxel with trastuzumab and pertuzumab
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel with trastuzumab and pertuzumab
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Overall treatment (pertuzumab, trastuzumab, and taxane)
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Docetaxel-containing therapy
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Paclitaxel-containing therapy
Number of subjects: 1436
Study: 30797139

Group type: EXPERIMENTAL
Intervention: Bendamustine and rituximab (BR) as first-line treatment
Number of subjects: 83
Study: 30797141

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 278

Group type: COMPARATOR
Intervention: PF (cisplatin and fluorouracil)
Number of subjects: 278
Study: 30797384

Group type: EXPERIMENTAL
Intervention: Home-based brief intervention for parents using cognitive-behavioral (CB) and motivational interviewing (MI) strategies
Number of subjects: 0
Study: 30797575

Group type: EXPERIMENTAL
Intervention: Opioid prescription and pain management
Number of subjects: 372
Study: 30797634

Group type: EXPERIMENTAL
Intervention: ACE527 vaccine with dmLT adjuvant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (unimmunized controls)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACE527 vaccine without adjuvant
Number of subjects: 60
Study: 30797636

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-based vaccines (PPV and/or PCV/PPV)
Number of subjects: 0
Study: 30798615

Group type: EXPERIMENTAL
Intervention: BNP, NT-proBNP, hs-cTnT, hs-cTnI concentrations
Number of subjects: 1538

Group type: COMPARATOR
Intervention: EGSYS (Evaluation of Guidelines in Syncope Study)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Death and major adverse cardiac events at 30 and 720 days
Number of subjects: 1538

Group type: COMPARATOR
Intervention: ROSE, OESIL, SFSR, CSRS
Number of subjects: 1538
Study: 30799546

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) group
Number of subjects: 41

Group type: COMPARATOR
Intervention: No-MTH group
Number of subjects: 41
Study: 30800095

Group type: EXPERIMENTAL
Intervention: Body Weight Support Combined With Treadmill Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0